Veterinary Reference Laboratory Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Growing uptake of pet insurance and higher veterinary spend

Premiums reached USD 4.5 billion in 2024, more than doubling since 2019. Concentrated underwriting among the top ten insurers heightens reimbursement standardization, which in turn lifts acceptance of advanced diagnostics. Veterinary cost inflation of 8.24% reinforces the value proposition of insurance and encourages owners to authorize comprehensive testing without cost anxiety..

Technology advances in immuno- and molecular diagnostics

AI-enabled platforms such as Zoetis Vetscan Imagyst now deliver cytology, hematology, and urine-sediment readings inside the clinic. Next-generation sequencing cancer panels achieve 92.7% detection accuracy and reveal actionable genomic variants for therapeutic planning frontiersin.org. Multiplex PCR assays detect pathogens at 10 copies/µL while matching national reference standards.

Rising companion animal population and pet-humanization trend

U.S. households owned 87.9 million dogs and 73.8 million cats in 2024, and canine patients generated 81% of practice revenue. Owners increasingly demand human-grade diagnostics, evidenced by an 80% accuracy rate of liquid-biopsy cancer monitoring compared with 41% for conventional imaging.

Increasing prevalence of zoonotic and chronic animal diseases

More than 800 U.S. dairy herds experienced H5N1 infection during 2024, and 38 human cases were reported in California, spurring mandatory surveillance across species^{[1]Source: Centers for Disease Control and Prevention, “Human Cases of Highly Pathogenic Avian Influenza A(H5N1) — California,” cdc.gov}. Expanded pathogen range in horses and cattle underscores the One Health imperative.

High cost of advanced tests and lab automation

Fully automated systems carry steep capital requirements that many small clinics cannot absorb. Over 80% of China’s pet hospitals earn under 2.4 million yuan annually, constraining equipment upgrades. Mobile laboratories and cartridge-based analyzers mitigate barriers but still require upfront hardware investment.

Shortage of board-certified veterinary pathologists

Aging specialist cohorts in North America and Europe lengthen turnaround for histopathology and cytology. AI triage solutions and virtual consult platforms extend expertise but cannot fully replace human judgment

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Veterinary Reference Laboratory Market Segment Analysis

Immunodiagnostics held 42.98% of the veterinary reference laboratory market in 2025 based on entrenched use in routine screening. Molecular diagnostics, however, is forecast to compound at 10.48% through 2031 on the back of superior pathogen specificity, precision medicine, and shrinking run times. Multiplex PCR panels and next-generation sequencing propel this growth trajectory, supported by falling reagent costs and software automation. Immunodiagnostics’ installed base and clinician familiarity sustain its revenue, but competitive pressure steadily diverts high-value oncology and infectious disease testing toward molecular formats.

AI-enhanced cartridge analyzers bring molecular throughput into clinics, shortening result cycles from days to under an hour. Reference laboratories differentiate themselves with whole-genome and liquid biopsy services that inform targeted therapy selection. As test menus broaden, bundled subscription pricing models emerge, anchoring client loyalty and stabilizing cash flows. With these shifts, molecular platforms continue to capture incremental revenue while immunoassay providers add multiplex capability to defend share. Both segments fuel aggregate expansion of the veterinary reference laboratory market.

Clinical pathology accounted for 38.22% of 2025 revenues and remains indispensable for wellness exams and chronic-disease monitoring. Virology’s 11.05% CAGR outpaces every other application due to heightened H5N1 surveillance and mandatory influenza testing in livestock. Rapid antigen and RT-PCR panels, validated against national standards, dominate high-volume screening protocols and facilitate trade compliance. Regulatory emphasis on early detection prompts governments to subsidize virology capacity expansion in dairy, poultry, and equine sectors.

Meanwhile, antimicrobial-stewardship programs elevate bacteriology demand, and AI fecal-analysis systems accelerate parasitology adoption. Toxicology testing grows steadier, driven by rising pet exposure to household chemicals. Other niche applications appear as emerging pathogens and novel therapies require specialized assays. Collectively, diverse testing needs reinforce the growth prospects of the veterinary reference laboratory.

Companion animals represented 65.05% revenue in 2025 and are on track for a 10.74% CAGR through 2031 as owners seek human-equivalent care. Dogs contribute the bulk of samples, although feline-specific innovations, such as bulk-acoustic-wave thyroid assays, gain traction. Enhanced insurance reimbursement and willingness to fund oncology panels solidify companion animals as the mainstay of the veterinary reference laboratory market. In contrast, livestock testing, although smaller, benefits from stringent biosecurity and food safety rules. Cattle surveillance intensifies following dairy-related H5N1 incidents, and multiplex assays targeting porcine respiratory pathogens sustain demand in swine operations. These programs, together, reinforce the veterinary reference laboratory market’s resilience across various animal categories.

Continued growth in companion care cascades into specialized equine sports-medicine panels and exotic-pet diagnostics, diversifying laboratory revenue streams. Livestock providers invest in on-farm sampling logistics and pooled testing to manage cost. Technology transfer between companion and livestock domains accelerates assay innovation and platform scalability.

Veterinary clinics retained 48.05% share in 2025 but face stiff competition from fast-growing in-house and mobile laboratories, which post a 12.03% CAGR. Cartridge-based analyzers and cloud-linked microscopes empower clinicians to perform advanced assays without external referrals. Reference laboratories respond by offering specialized panels, guaranteed turnaround times, and integrated teleconsults. Veterinary hospitals leverage scale to deploy high-throughput analyzers, while start-ups design AI-driven interfaces that simplify the interpretation of complex assays.

Universities and research institutes maintain leadership in validation studies and novel assay development, providing a pipeline of technologies that are later commercialized by private laboratories. Telemedicine platforms blur the boundary between clinician and lab, funneling digital images and biometric data into cloud models for instant analytics. This multi-channel ecosystem enhances access, speed, and diagnostic depth, sustaining the broader veterinary reference laboratory market.

Geography Analysis

APAC Veterinary Reference Laboratory Market

Asia-Pacific is the fastest-advancing region at a 12.04% CAGR to 2031. China’s pet economy reached 300 billion yuan (USD 41 billion) in 2024 with veterinary care at 28% of spend, though profitability constraints in smaller clinics spur demand for cost-efficient diagnostics. Japanese innovators deploy AI-powered fecal analysis and after-hours tele-health, improving accessibility in an aging-society. Australia attracts multinational investment, as Zoetis expanded vaccine production capacity through a new Melbourne site. Varied regulatory frameworks and uneven infrastructure create a patchwork of opportunities across the region, yet rising household incomes and changing pet-owner behavior support sustained uptake of laboratory services.

North America Veterinary Reference Laboratory Market

North America maintained 38.90% market share in 2025 courtesy of mature practice infrastructure and high pet-care expenditure. FDA Guidance #263, effective June 2024, mandates prescription oversight for antimicrobials, indirectly boosting diagnostic volumes in food animals avma.org. Workforce shortages and declining clinic visits temper momentum, nudging providers toward automation to preserve productivity.

EMEA Veterinary Reference Laboratory Market

Europe demonstrates steady mid-single-digit expansion supported by regulatory harmonization and recent consolidation. Mars Incorporated completed acquisitions of SYNLAB Vet and Cerba Vet, enhancing test menu breadth and geographic reach . Antimicrobial-stewardship campaigns encourage diagnostics-guided therapy, and established veterinary training programs sustain demand for specialized assays. Emerging markets in the Middle East and Africa remain nascent yet promising, evidenced by the Philippines’ PHP 20 million investment in a new veterinary-diagnostic facility pna.gov.ph. Point-of-care platforms offer scalable options for regions lacking extensive laboratory networks, underlining a global convergence toward accessible diagnostics.

Regulatory Landscape

Regulation relevant to veterinary reference laboratories is anchored in official testing and surveillance requirements for notifiable animal diseases. In the United States, 9 CFR 71.22 ties certain official disease testing to USDA APHIS laboratory approval, with requirements around quality systems, use of approved methods, and ongoing oversight, including inspections. In February 2026, USDA APHIS NVSL highlighted work to enhance its laboratory approval portal and a work plan to amend 9 CFR 71.22, reflecting continued modernization of approval and oversight processes for regulated testing.

Accreditation and standards frameworks shape operational expectations globally, even when general reference lab services, such as routine CBCs and many hormone assays, are not directly overseen by USDA. AAVLD accreditation aligns with WOAH (OIE) quality standards for veterinary laboratories, and network participation, such as NAHLN assay deployment, uses multi-stage validation for analytical and diagnostic performance before acceptance. In Europe, EU Regulation 2019/6 on veterinary medicinal products, alongside EMA and national competent authority oversight, reinforces a broader compliance backdrop around antimicrobial stewardship and traceability, which indirectly supports demand for standardized, validated diagnostics that reference laboratories can provide.

Market Opportunities and Future Outlook

Hybrid models that pair centralized reference-lab capacity with digital reading, consult, and workflow tools are expanding the value per case. Zoetis placing a 32,000-square-foot reference laboratory at the UPS Healthcare Labport in Louisville (opened May 2025) illustrates how locating high-complexity testing near major logistics infrastructure compresses specimen transit time and supports faster turnaround for send-out testing, a key lever for clinics that mix in-house testing with advanced panels that still depend on reference-lab depth.

Genomics and NGS-based infectious disease and parasitology testing are creating gaps where culture-based or singleplex methods are slower or inconclusive. MiDOG Animal Diagnostics expanded whole genome sequencing services in March 2026, including antimicrobial resistance and virulence profiling, and then launched a dedicated NGS-based parasite detection test in July 2026, demonstrating how sequencing-led workflows move into commercial testing for complex, polymicrobial, or low-burden infections. In parallel, virtual reference-lab capabilities are being integrated more tightly into service delivery, and Zoetis' announced agreement in July 2026 to acquire VitalRADS, a cloud-based veterinary teleradiology platform, points to opportunities for reference laboratories and integrated providers to bundle imaging interpretation, AI-assisted decision support, and lab results into a single clinician workflow and subscription-oriented service layer.